World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQLEXX)NASDAQ:LEXXWNASDAQLEXXW)

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss

North American drug delivery development experts added to help guide Lexaria's strategic plans

Dr. Gibson joining Lexaria's new scientific advisor board

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format

DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

DehydraTECH clinical test article manufacturing has been completed

DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format

KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the "Stockholder Approval Date") and will expire five years from the Stockholder Approval Date.

KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQLEXX)NASDAQ:LEXXWNASDAQLEXXW)

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQLEXX) & NASDAQ:LEXXWNASDAQLEXXW)

KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQLEXX) & NASDAQ:LEXXWNASDAQLEXXW)

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka discussed Lexaria’s performance in the capital markets; the company’s Phase 1b DehydraTECH-CBD hypertension trial and Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study; ongoing R&D; and his reason for stepping aside from his role as CEO.